Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.50)
# 1,093
Out of 4,655 analysts
204
Total ratings
44.6%
Success rate
15.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies | Maintained: Buy | $184 | $83.01 | +121.66% | 3 | Aug 17, 2026 | |
| SRZN Surrozen | Maintained: Buy | $46 | $23.78 | +93.44% | 8 | Aug 17, 2026 | |
| ACHV Achieve Life Sciences | Maintained: Buy | $17 | $7.50 | +126.67% | 4 | Aug 15, 2026 | |
| KOD Kodiak Sciences | Maintained: Buy | $65 → $85 | $40.98 | +107.42% | 12 | Aug 15, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 → $63 | $36.68 | +71.76% | 13 | Aug 11, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Buy | $12 | $3.40 | +252.94% | 46 | Aug 10, 2026 | |
| OCS Oculis Holding AG | Rated: Buy | $45 → $41 | $13.14 | +212.02% | 10 | Aug 8, 2026 | |
| MBX MBX Biosciences | Rated: Buy | $91 → $121 | $68.25 | +77.29% | 8 | Aug 8, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $104 | $53.76 | +93.45% | 13 | Aug 6, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.45 | +244.83% | 12 | Jul 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $11.34 | +67.55% | 1 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $70.62 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $41.40 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $4.32 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.7001 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $41.92 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $4.70 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €4.05 | n/a | 8 | Jun 16, 2020 |
Sol-Gel Technologies
Aug 17, 2026
Maintained: Buy
Price Target: $184
Current: $83.01
Upside: +121.66%
Surrozen
Aug 17, 2026
Maintained: Buy
Price Target: $46
Current: $23.78
Upside: +93.44%
Achieve Life Sciences
Aug 15, 2026
Maintained: Buy
Price Target: $17
Current: $7.50
Upside: +126.67%
Kodiak Sciences
Aug 15, 2026
Maintained: Buy
Price Target: $65 → $85
Current: $40.98
Upside: +107.42%
Neurogene
Aug 11, 2026
Maintained: Buy
Price Target: $65 → $63
Current: $36.68
Upside: +71.76%
Rocket Pharmaceuticals
Aug 10, 2026
Maintained: Buy
Price Target: $12
Current: $3.40
Upside: +252.94%
Oculis Holding AG
Aug 8, 2026
Rated: Buy
Price Target: $45 → $41
Current: $13.14
Upside: +212.02%
MBX Biosciences
Aug 8, 2026
Rated: Buy
Price Target: $91 → $121
Current: $68.25
Upside: +77.29%
Structure Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $104
Current: $53.76
Upside: +93.45%
iBio, Inc.
Jul 1, 2026
Maintained: Buy
Price Target: $5
Current: $1.45
Upside: +244.83%
Jun 17, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $11.34
Upside: +67.55%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $70.62
Upside: n/a
Nov 11, 2023
Maintained: Buy
Price Target: $6
Current: $41.40
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $4.32
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.7001
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $41.92
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $4.70
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €4.05
Upside: n/a